OneDigital Investment Advisors LLC Sells 4,300 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

OneDigital Investment Advisors LLC lowered its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 27.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,399 shares of the biopharmaceutical company’s stock after selling 4,300 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Amicus Therapeutics were worth $122,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of FOLD. Janus Henderson Group PLC grew its stake in shares of Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. Millennium Management LLC grew its position in Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter. William Blair Investment Management LLC increased its stake in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after buying an additional 1,477,084 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Amicus Therapeutics by 141.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock worth $21,765,000 after buying an additional 1,192,489 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its stake in shares of Amicus Therapeutics by 159.1% in the 2nd quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 399,449 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,398,532.40. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on FOLD shares. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Guggenheim lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald increased their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Bank of America lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Price Performance

FOLD opened at $9.66 on Friday. The firm has a 50-day moving average price of $10.82 and a 200-day moving average price of $10.58. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $2.89 billion, a price-to-earnings ratio of -28.41 and a beta of 0.68.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.